Here are the Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Clinical characteristics affecting perception, clinical characteristics affecting weight loss in face, clinical characteristics affecting weight lifting, clinical characteristics affecting weight loss in an elderly person, clinical characteristics affecting weight loss in ankylosing, clinical characteristics of angelman, clinical characteristics meaning, clinical characteristics affecting weight chart.
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis
Objective: To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.
Methods: In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks. A subset of Japanese participants with type 2 diabetes (T2D) was also included. In this post-hoc analysis, change from baseline in BW (%) was assessed by subgroups of baseline characteristics including baseline BW, body mass index, age, sex, glycemic status, dyslipidemia, and hypertension.
Results: Of 401 participants (148 female and 253 male) included, the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from –9.40 % to –16.42 %. Estimated treatment differences also favored both semaglutide doses versus placebo. Significant treatment-by-subgroup interactions were observed for s ex with semaglutide 1.7 mg and 2.4 mg versus placebo at week 68 (p = 0.0008 and p = 0.0005, respectively). Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively). Conclusions: Semaglutide reduces BW in a wide demographic of people with a range of weight-related comorbidities in an East Asian population. © 2025
Authors : Kadowaki T.; Lee S.Y.; Ogawa W.; Nishida T.; Overvad M.; Tobe K.; Yamauchi T.; Lim S.
Source : Elsevier Ltd
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1016/j.orcp.2025.01.002 |
| ISSN | 1871403X |
| Volume | 18 |
You can download the article here
If You have any problem, contact us here